Full Text View
Tabular View
No Study Results Posted
Related Studies
Solifenacin Succinate (VESIcare) for the Treatment of Overactive Bladder in Parkinson's Disease (URGE-PD)
This study is currently recruiting participants.
Verified March 2012 by University of South Florida
Study NCT01018264   Information provided by University of South Florida

First Received on November 19, 2009.   Last Updated on March 26, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Additional conditions recognized in this trial
Parkinson Disease
Urinary Bladder, Overactive
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Signs and Symptoms
Urinary Bladder Diseases
Urologic Diseases
Urological Manifestations
Interventions listed in this trial
solifenacin succinate (VESIcare)
placebo
Additional drug interventions recognized in this trial
Quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate
More general drug interventions related to this trial
Cholinergic Agents
Cholinergic Antagonists
Molecular Mechanisms of Pharmacological Action
Muscarinic Antagonists
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
University of South Florida
Astellas Pharma Inc


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services